Overview

A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804

Status:
Terminated

Trial end date:
2012-05-01

Target enrollment:
0

Participant gender:
All

Summary

This study will enroll patients who are planned to undergo surgical removal of their tumor. The goal of the study is to evaluate the changes that occur in the tumor after brief (about 8 days) exposure to the study drug.

Phase:

Phase 1

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Pfizer

Criteria

Inclusion Criteria:

- Radiographs consistent with lung cancer for which resection is indicated upon
histologic confirmation of non-small cell lung cancer.

- Patient willing to take PF-00299804 for 5 to 11 days and provide blood and tissue
specimens as required in the study.

Exclusion Criteria:

- Prior or concurrent systemic anticancer therapy for cancer (immunotherapy,
hormonotherapy, biological therapy, or chemotherapy) less than one year from time of
consent.

- Prior or concurrent radiation therapy to tumor at site of planned resection.

- Congestive heart failure (LVEF < 50%), uncontrolled hypertension, significant
ventricular arrythmia.

- Drugs that are highly dependent on CYP2D6 for metabolism, or are generally accepted to
have a risk of causing Torsades de Pointes.

- Prior or concurrent radiation therapy to tumor at site of planned resection.